News Press Releases

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Tesaro Incorporated To Contact The Firm

YELP | February 20, 2018

DEADLINE ALERT: Brower Piven Reminds Investors Of Upcoming Deadline In Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Tesaro Incorporated To Contact The Firm

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of purchasers of Tesaro Incorporated (Nasdaq: TSRO) (“Tesaro” or the “Company”) securities during the period between March 14, 2016 and January 12, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 19, 2018 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Tesaro securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that substantial undisclosed health risks, including anaphylaxis and anaphylactic shock, were associated with Tesaro’s intravenous formulation of Varubi.

According to the complaint, following a January 12, 2018 announcement that Tesaro had updated the U.S. labeling for the intravenous formulation of Varubi and that it had issued a “Dear Healthcare Professional” letter, the value of Tesaro shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Tesaro securities purchased on or after March 14, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.